Fig. 4: Oncoprint representing distribution of oncogenic and variants of uncertain significance (VUS) in ctDNA at baseline.

Cohort 1 includes patient identifications listed as NEC-2–27 (n = 13), and Cohort 2 includes patient identifications listed as NEC-29–48 (n = 11). p: second sample.